Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- MTPC Aims at Over 17% Share for SGLT-2 Inhibitor Canaglu in Japan: Sales Division Head
August 28, 2014
- Otsuka Holdings Takes Aim at 915 Billion Yen Pharma Sales in FY2018 after Abilify Patent Loss
August 27, 2014
- Fixed-Dose Combination HIV Treatment Triumeq Approved in US: ViiV Healthcare
August 27, 2014
- AnGes MG Resumes Development of NF-κB Decoy Oligo Ointment Formulation for Atomic Dermatitis
August 26, 2014
- Chugai to Restrict Use of Alecensa to Medical Institutions, Doctors that Meet Specified Conditions
August 26, 2014
- AnGes MG Revamps US Unit to Prepare for Global PIII Study of Collategene
August 25, 2014
- Janssen Files Anti-HIV Combination Tablet for Approval
August 25, 2014
- Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
- Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
- Nichi-Iko to Launch Own Products in Thailand in October
August 22, 2014
- Carfilzomib Monotherapy Fails to Meet Primary Endpoint in PIII: Amgen, Onyx
August 22, 2014
- MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
- Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe
August 21, 2014
- Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
- Launch of Daiichi Sankyo Espha’s Cravit Generics Not Yet Determined
August 20, 2014
- Daiichi Sankyo Starts PIII Study of Etanercept Biosimilar, Eying Approval in FY2016
August 20, 2014
- Approval Conditions Lifted for Tykerb: GSK
August 20, 2014
- Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
- Eisai Licenses Pariet Successor to Zeria
August 19, 2014
- Eisai Files for Regulatory Approval of Lenvatinib in US, Europe
August 19, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…